Mesenchymal stem cells used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy by Mahasa, Khaphetsi Joseph et al.
1Scientific RepoRtS |          (2020) 10:425  | https://doi.org/10.1038/s41598-019-57240-x
www.nature.com/scientificreports
Mesenchymal stem cells used as 
carrier cells of oncolytic adenovirus 
results in enhanced oncolytic 
virotherapy
Khaphetsi Joseph Mahasa1,2*, Lisette de pillis3, Rachid ouifki  2, Amina eladdadi4, 
philip Maini5, A-Rum Yoon6 & Chae-Ok Yun6*
Mesenchymal stem cells (MScs) loaded with oncolytic viruses are presently being investigated as a 
new modality of advanced/metastatic tumors treatment and enhancement of virotherapy. MSCs can, 
however, either promote or suppress tumor growth. To address the critical question of how MSCs 
loaded with oncolytic viruses affect virotherapy outcomes and tumor growth patterns in a tumor 
microenvironment, we developed and analyzed an integrated mathematical-experimental model. We 
used the model to describe both the growth dynamics in our experiments of firefly luciferase-expressing 
Hep3B tumor xenografts and the effects of the immune response during the MSCs-based virotherapy. 
We further employed it to explore the conceptual clinical feasibility, particularly, in evaluating the 
relative significance of potential immune promotive/suppressive mechanisms induced by MSCs loaded 
with oncolytic viruses. We were able to delineate conditions which may significantly contribute to the 
success or failure of MSC-based virotherapy as well as generate new hypotheses. In fact, one of the 
most impactful outcomes shown by this investigation, not inferred from the experiments alone, was 
the initially counter-intuitive fact that using tumor-promoting MSCs as carriers is not only helpful  
but necessary in achieving tumor control. considering the fact that it is still currently a controversial 
debate whether MSCs exert a pro- or anti-tumor action, mathematical models such as this one help  
to quantitatively predict the consequences of using MSCs for delivering virotherapeutic agents  
in vivo. Taken together, our results show that MSC-mediated systemic delivery of oncolytic viruses is a 
promising strategy for achieving synergistic anti-tumor efficacy with improved safety profiles.
For most advanced or metastatic tumors, only a limited number of therapeutic options are available for cancer 
patients. Oncolytic viruses (i.e. viruses that selectively replicate and destroy cancer cells while having limited or no 
toxicity to normal cells) have emerged as promising novel therapeutic strategy against most advanced types of cancers. 
Their delivery to tumor sites, however, remains a major obstacle. When oncolytic viruses (OVs) cannot be injected 
directly into a target tumor, only a limited fraction (usually administered intravenously) manage to migrate and reach 
the target tumor site. This is often due to antiviral immunity in the blood which rapidly clears the viruses1,2. Clinical 
evidence indicates that even for high doses of intravenous OVs, the efficient systemic delivery of OVs is still limited3,4.
To overcome these challenges, several strategies have been explored including the use of cells that have the 
potential to home in towards the tumor microenvironment as delivery vehicles for OVs5,6. Some carrier cells are 
used as Trojan horses which can internalize the OVs and allow virus replication, but have no role after successful 
OV delivery in tumor sites7.
In recent years, MSCs have been identified as promising vectors for the delivery of anti-cancer agents due to 
their strong inherent tropism into the tumor microenvironment where they not only constitute cellular com-
ponents, but also regulate tumor growth8. While within the tumor microenvironment, MSCs can interact with 
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tumor cells in several ways which may result in the promotion of tumor growth9,10. This mechanisms include 
suppression of local immune response11,12, stimulation of the epithelial–mesenchymal transition13, promotion of 
angiogenesis10,14, inhibition of tumor cell apoptosis, and promotion of tumor metastasis9,15.
Another important attribute of MSCs which often make them attractive candidates for OVs delivery, is 
that they support viral replication while loaded with the virus11,12,16. MSCs are also known to protect (through 
internalization) the pre-loaded virus from immune-mediated neutralization during their migration to tumor 
sites12,17,18. Building on this, recent experimental studies show that MSCs not only hide the pre-loaded OVs from 
immune cells during their trafficking to the tumor site, but they can also suppress the immune response11,12. It is, 
however, not fully understood how MSCs precisely suppress the immune system11. In contrast to their tumor pro-
moting abilities, several studies report that MSCs can also suppress tumor growth9,19. MSCs can inhibit growth 
of tumor cells through inhibition of angiogenesis20, induction of cell cycle arrest and apoptosis21, enhancement 
of inflammatory infiltration22, and inhibition of proliferation-related signaling pathways, such as Wnt9,23. Despite 
that, it is still not fully understood how MSCs facilitate the inhibition of tumor cell growth because no study has 
precisely indicated which ligand is responsible for the induction of tumor growth suppression9. Currently, it is still 
controversial whether MSCs suppress or promote tumor development8. Given the lack of information on the local 
interactions involved within the tumor microenvironment upon the arrival of OV carrier cells, we investigate 
whether using MSCs as OV carriers can significantly contribute to tumor cell death (lysis) induced by OVs upon 
their arrival at the tumor microenvironment.
In spite of these tumor-promotive/suppressive mechanisms, multiple challenges remain to be fully addressed 
before MSC-based virotherapeutic approaches can be routinely applied in clinical settings. MSCs derived from 
different tissues in a patient can produce widely varying outcomes in relation to secretion of cytokines and 
chemokines, and immunomodulatory potential24–26. Hence, it becomes difficult to predict how different patients 
will respond to the MSC-based cell carrier therapies25.
Currently, there is a small number of experimental-mathematical models that address the challenge of low 
delivery of therapeutic agents to the tumor microenvironments. Such models include use of nanoparticles27–29 and 
macrophages30,31 to deliver therapeutic drugs to tumor sites. There is, however, no mathematical model that has inves-
tigated the use of highly unpredictable mesenchymal stem cells in the presence of active immune response in onco-
lytic virotherapy. Thus, our modeling approach aims to bridge this gap. In an effort to better understand the current 
limitations of oncolytic virotherapy and how we might redesign better and successful virotherapies, it is invaluable to 
adopt an integrated mathematical-experimental approach. Mathematical modeling provides a theoretical framework 
that can be used both descriptively and predictively to explain the complexity of the tumor-immune-therapy inter-
actions. A quantitative understanding of these interactions would help to design better and successful MSC-based 
virotherapies. In this contribution, we develop a mathematical model calibrated with our in vivo and in vitro experi-
ments32 to investigate the tumor response to the use of MSCs as cellular delivery vehicles for OVs.
Materials and Methods
Experiments: Oncolytic adenovirus delivery by mesenchymal stem cells. The study protocol was 
in accordance with the declaration of Helsinki. After receiving the informed consent, bone marrow was obtained 
from healthy donors. All the manufacturing and product testing procedures for hMSC generation were per-
formed using good manufacturing practices (Pharmicell Co. Ltd., Seongnam, Korea). This research protocol was 
reviewed and approved by Institutional Review Board of Asan Medical Center, Seoul, Korea (2015–1123). All 
aspects of animal care and treatment were performed in a facility approved by the Association for Assessment 
and Accreditation of Laboratory Animal Care. All animal studies were performed according to the institutionally 
approved protocols of University of Utah and Hanyang University. All mice were housed for 1 week for acclimati-
zation, and ad libitum access to food and water was provided. The experiment for assessing MSCs as cell carriers 
of oncolytic Ads was carried out for both in vitro and in vivo settings as follows32.
In vivo tumor growth analysis. The experimental design of using mesenchymal stem cells (MSCs) as 
cell carriers of oncolytic Ad and tumor growth data in response to oncolytic Ad has been reported in32. The 
study evaluates the therapeutic efficacy of oAd-loaded MSCs on luciferase-expressing orthotopic Hep 3B tum-
ors which were treated with phosphate buffered saline (PBS), MSCs, oncolytic adenovirus (oAd), and MSCs 
infected with oAd (oAd-MSCs). The orthotopic hepatocellular carcinoma cancer model was established by inject-
ing 1 × 106 firefly luciferase-expressing Hep 3B cells into the left lobe of the liver in athymic nude mice. At 7 
days post-implantation, blood was harvested by retro-orbital bleeding, and the level of AFP was analyzed by 
enzyme-linked immunosorbent assay (ELISA) according to manufacturer’s instruction. The mice were randomly 
divided into three groups by serum AFP level and treated with an intravenous injection of PBS, 1 × 106 MSCs, 
5 × 108 virus particles (VP) of oncolytic Ad, and oAd-MSC (1 × 106 MSCs infected with 5 × 108 VP of oncolytic 
Ad) on day 9 and 13 post-tumor cell implantation (n = 6 per group). Optical imaging, with an IVIS SPECTRUM 
instrument, was conducted every week and luciferase activity was quantitatively analyzed with IGOR-PRO Living 
Image software. A group of tumor-bearing mice that were treated with PBS served as controls.
Mathematical model. Biological assumptions. Since cell migration, or trafficking, occurs across com-
plex multiple cellular networks, we assume, for simplicity, that MSCs have successfully homed in to the tumor 
sites where they can deliver their therapeutic payloads. Note that in this study, we do not consider the mecha-
nisms that induce MSC migration to tumor sites, but we model the local interactions between MSCs loaded with 
oncolytic Ads (oAd-MSCs), free oncolytic Ads within the tumor microenvironment, immune cells, and tumor 
cells. We also assume that the oncolytic Ads are successfully pre-loaded MSCs. Here, MSCs are not only used as 
Trojan horses, but as cells that can also interact with tumor cells and, possibly, promote tumor growth or induce 
tumor suppression. Furthermore, we assume that there are other local immune lymphocytes within the tumor 
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microenvironment: Natural killer (NK) cells and activated cytotoxic T lymphocytes (CTLs). While there are more 
than 10 types of immune cells, we included the main components of the immune system that are relevant to onco-
lytic virotherapy. The viral-tumor specific T cell (CTL) response contributes to the efficacy of oncolytic Ad therapy 
by improving tumor oncolysis and mediating a long-term anti-tumor immune response33, while NK cells, as part 
of the innate immune response, are recruited and activated to clear both OVs and infected tumor cells following 
initial OV treatment34. Upon their release from oAd-MSCs, for simplicity, we assume that OVs can only interact 
with tumor cells at the tumor site, even though it is possible that viruses can also interact with immune cells35,36.
Using this new integrated mathematical-experimental framework, our major goals are two-fold: (1) to inves-
tigate the efficacy of oAd-MSCs treatment and the immune response to tumor cells. (2) to compare the oAd-MSC 
dosing regimen (i.e., when MSCs are used as delivery vehicles of oncolytic Ads) with the direct dose of naked 
oncolytic Ad regime, from a quantitative perspective.
Our model builds upon the following biological assumptions: (a) in the absence of immune response and 
OVs, tumor growth is characterized by logistic growth dynamics; (b) as part of the innate immunity, NK cells 
are always present in the tumor microenvironment, even in the absence of tumor cells, while CTLs are present 
only when a tumor is present; (c) after lysis of MSCs, OVs infect tumor cells. Since not all viruses can success-
fully infect tumor cells, we assume that free viruses are cleared by the antiviral immune cells within the tumor 
microenvironment; (d) the oAd-MSCs can only promote or suppress growth of the proliferating uninfected 
tumor cells since the life-span of infected cells is short (i.e., the virus rapidly lyses the infected cell as modeled 
in37); (d) we assume that the tumor microenvironment and cell populations are spatially homogeneous. (e) We 
also assume that there is no genetic variability within one cell population. It is known that tumor heterogeneity is 
important, but in this model, for simplicity, we assume that the model describes the average behaviour of a cell.
State variables and parameters. The mathematical model is based on the interaction network illustrated in Fig. 1. 
The independent variable is time, t, and the state variables considered in this model are as follows: Tu(t), the total 
number of uninfected tumor cells; Ti(t), the total number of infected tumor cells; Mi(t), the total number of MSC 
carriers in the tumor microenvironment (oAd-MSC); V(t), the total number of virions released within the tumor 
microenvironment; EK(t), the total number of NK cells within the tumor microenvironment; and EC(t), the total 
number of activated CTLs within the tumor microenvironment. The model parameters, together with their units 
and sources, are summarized in Table S1.
Key Equations:
  

























































Figure 1. Model interaction network within the tumor microenvironment. Oncolytic Ad carrier cells: MSC 
loaded with OVs (Mi) undergo lysis (Short dash line) resulting in release of free oncolytic Ads (V). oAd-MSCs 
promote/suppress tumor cell proliferation (Long dash line). Uninfected tumor cells (Tu) become infected 
cells (Ti) upon successful entry of the virus (Dash dot line). Infected cells also undergo lysis (Short dash line) 
resulting in more free viruses. Cytotoxic immune cells: Natural killer cells (EK) and cytotoxic T lymphocytes 
(EC) kill tumor cells (Solid line) and clear free viruses (Round dot line).
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The functional form, D in Eq. (7), represents a ratio-dependent tumor cell kill by activated CTLs, derived 
in38. The parameters, α and l, denote the maximum fractional tumor cell lysis by CTLs and a CTL strength scal-
ing exponent, respectively. The parameter hEC in D represents the activated CTL toxicity constant that supports 
half maximum CTL killing rate. η is the tentative tumor growth promotive/suppressive constant induced by 
oAd-MSCs. Since to our knowledge the number of tumor cells promoted/suppressed by MSCs, η, has not been 
measured experimentally, we chose to focus on the overall MSC promotive/suppressive effect (δp/sη), where δp/s 
is the probability that an interaction between an MSC and a tumor cell results in promotion/suppression of 
tumor proliferation. In model simulations, for illustrative purposes, we use a baseline value of δp/sη = 0.5 × 4 = 
2 cells/day. Thus, to demonstrate the potential confounding mechanisms of promotion/suppression of tumor cell 
proliferation induced by oAd-MSCs, the simulations are run to ensure that at least 2 tumor cells are suppressed 
by oAd-MSC. In the case where simulations consider much larger values of η than the assumed baseline value, 
such adjustments will be addressed accordingly in their respective sections. The rest of the model parameters are 
summarized in Table S1.
Oncolytic Ads have been shown to successfully replicate within and lyse both tumor cells and MSCs11,12,16, and 
for this reason we assume that the cell death response function lv(MOI) is a Hill-like function of the multiplicity 











n and n denote the amount of virions (virus particles) necessary to generate half-maximal 
cell death and the scaling exponent (coefficient) of the Hill function, respectively. The Hill-like function of the 
multiplicity of infection governs the lysis rate of infected cells by oncolytic Ads which, essentially, depends on 
MOI (see Appendix B in the SI text). In this study, we emphasize that the higher the MOI, the higher the lysis of 
the infected tumor cells18. We also emphasize that the proposed model does not take into account multiple infec-
tion. The Hill function we use in Eq. (10) reflects the effects of an OV on infected cells by accounting for the 
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phenomenon where the lysis, lv, approaches the maximum value (denoted by 1), whenever MOI approaches 
higher values (i.e., at higher virus loading). Higher values of the exponent n > 1 increase the sensitivity of infected 
cells (oAd-MSCs or tumor cells) to infection of adenovirus. A complete description of the model interactions and 
the parameter estimates is presented in the SI text.
Initial conditions and lysis. Since the model was used to investigate different treatment scenarios, each scenario 
has a set of initial conditions. We use in vitro oAd-MSC data to inform the model parameters on cell lysis of 
infected MSCs. We assumed the same virus-mediated lysis for tumor cells because the results in32 illustrate a MOI 
(dose)-dependent killing of tumor cells. The cell lysis is, ideally, different in MSC and hepatocellular carcinoma 
(HCC) cells, since virus replicates more proficiently within HCC. Although we can quantify the oncolytic Ad 
virus particles released from the MSC as a result of virus replication-mediated cytolysis, it is generally difficult to 
determine how many virus particles would successfully infect tumor cells. The released virus particles within the 
hostile tumor microenvironment may be subjected to manifold factors that may hinder their entry into tumor 
cells39. Thus, for simplicity, we assume the same virus-mediated lysis function for both oAd-MSCs and tumor 
cells. A detailed description of our initial conditions and the parameter estimates is presented in Appendix A in 
the SI text.
Data fitting and parameter estimation. To validate our model, we use an iterated local search-based method 
which consists of (a) obtaining a local minimum by means of the iterative descent algorithm and (b) randomly 
changing some of the model parameters and performing another iterative descent algorithm to find a better min-
imum. The goodness of fit is measured as the residual sum of squares (RSS) between the log of the experimental 
data and that of the model estimates. The variability among the measured tumor growth curves and response to 
oncolytic Ad, as well as the oAd-loaded MSC cell viabilities, requires a succinct explanation of data fitting and 
parameter estimation. We used our model described by Eqs. (1–4) to simultaneously fit the data of Fig. 5(B) of 
Yoon et al.32, which corresponds to treatment using oncolytic Adenovirus (oAd) and mesenchymal stem cells 
(MSC) alone, and a combined treatment of oAd and MSCs. The model fitting was done with the variables EK 
and EC set to zero because the experimental data in32 were obtained from immunodeficiency mice which do 
not mount any immune response to the tumor and/or virus. The experimental data were collected under the 
following conditions: (i) phosphate buffered saline (PBS) (used as treatment control), (ii) mesenchymal stem 
cells (MSC), (iii) oncolytic adenovirus (oAd), (iv) MSCs infected with oAd (oAd-MSCs). These cells/viruses were 
intravenously injected into tumor-bearing mice at 9 and 13 days after the tumor cell injection. Tumor growth was 
recorded weekly and represents the average of 1–4 orthotopic tumor models. All data sets contain measurements 
of luciferase-expressing orthotopic Hep 3B tumor sizes indicated by bioluminescence signal intensity obtained as 
photons acquired per second (p/s) from regions of interest [see32, Fig. 5(A,B)]. We fit the submodel solutions of 
the system described by Eqs. (1–4). For comparing treatment efficacies, treated tumor growth curves (i.e., with 
either oAd or oAd-MSC) were paired to PBS (regarded as control) and simultaneous fitting was performed for 
each pair. For the control case (PBS), we fit the logistic submodel defined by Eq. 1, to estimate tumor growth rate, 
Figure 2. Tumor data and model simulations. Tumor growth data, in the absence of therapy, were fitted to 
logistic equation (A) and to the treatment with oAd-MSC in (B). In (A,C), the diamonds represent plots of the 
untreated tumor (PBS) while the dashed lines denote the model prediction. Similarly, the stars correspond to 
the oAd-MSC treamtment data while the solutions of the system of Eqs. (1–4) are fitted to the oAd-MSC data 
with a solid line in (A,C). Our model fits both sets of experimental data well and this fitting enabled robust 
parameter estimation. In (B,D), a significant tumor reduction is exhibited by a monotonic decrease in size of 
infected tumor cell population after it reaches a maximum. The oAd-MSC treatment had effectively reduced 
tumor growth compared either to oAd monotreatment or to the control case (without treatment). These 
simulations were conducted using the following parameters: (δp/s = 0), Tu0 = 2.6 × 106, KT = 2.54 × 109, MOI = 5, 
with other parameters as in Table S1 in SI text.
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aT, in the absence of treatment. For other tumor-virus related parameters, infection rate of tumor cells (βT), burst 
sizes of infected tumor cells (bT), and in vivo burst size of oAd-MSC (bM), we used the corresponding treated 
tumor growth data to fit the corresponding submodel given by Eqs. (1–4). Additionally, we estimate the cell death 
rate (lysis rate) of infected cells using Eq. 9 for a specific MOI and retained this estimate for subsequent model 
simulations. To further understand the cell viability of oAd-loaded MSCs for all MOIs, we used an appropriate 
exponential response function (See Supplementary Fig. S6 in the SI text).
Results
Model validation and parameter estimation. First, we fit the data corresponding to treatment case 
(i) with PBS alone. In this case, we used a model that excludes the virus infection and induced tumor/virus spe-
cific immune responses. We obtained aT = 0.315/day and retained this estimated value for all subsequent model 
simulations. For other remaining tumor-virus related parameters, we sequentially and hierarchically fitted the 
model parameters to appropriate data sets and obtained the estimates in Table 1 in the SI text. The example plot 
of both untreated and treated tumor growth data and model solutions fitted to the oAd-MSC treated mice with 
the measured tumor load Tu(t) + Ti(t) is shown in Fig. 2. In Fig. 2 we show representative plots of the model fits 
to experimental data in32. Since in the data it was difficult to determine which cell is infected, the total tumor size 
(Tu(t) + Ti(t)) was measured and the model fitted to the data. The significant reduction of tumor size can clearly 
be observed by tracking the infected tumor cell population (Fig. 2(B,D)). We note that in the presence of the oAd-
MSC, tumor growth is invariably slowed down compared to either oAd treatment or the control case (PBS) at 35 
days post tumor implantation, as expected. Consequently, the survival of the oAd-MSC treated mice improves 
with therapy.
predictions and insights from the mathematical model. To better understand the interaction mech-
anisms of oAd-MSCs in the tumor microenvironment and the effect of MSC-based treatment, we used our new 
mathematical model to simulate the response of tumor cells to oAd-MSCs. We used our model to provide insights 
on the optimal use of MSC-based therapeutic strategies for maintaining a lower tumor burden.
The model simulations were based on the following schedule: (1) We first identify the key model parameter 
using global sensitivity analysis. (2) We simulate the long-term behavior of the model in the absence of therapy 
(i.e., without the oAd-MSC treatment and the immune response to tumor cells). (3) We then use the compu-
tational model to explore various critical properties of MSCs and oncolytic viruses. (4) Finally, we perform an 
in silico therapy to capture the dynamics between the tumor cells, oAd-MSCs, virus populations released from 
oAd-MSCs and immune cells within the tumor microenvironment. However, due to lack of appropriate data eval-
uating the tumor promotion or suppression by oAd-MSCs, our mathematical model only presents a conceptual 
study illustrating the dynamic consequences of local interactions of the tumor-oAd-MSC-immune ecosystem 
within the tumor microenvironment. Hence, we should be cautious in making certain statements about specific 
oAd-MSC treatment responses, and any simulation should be interpreted as one possibility, and not as an inevita-
ble treatment outcome in any given case. However, a large number of model simulations, along with model sensi-
tivity analysis of parameter fluctuations, can certainly provide a general overview of possible cell-virus dynamics 
under certain conditions. Further investigations into these mechanisms may generate new insights into the nature 
of the tumor-oAd-MSC-immune system interactions, as well as effective treatment regimes in oncolytic virother-
apy. Next, we highlight four key outcomes from our model simulations.
Figure 3. Consequences of oAd-MSC therapy on primary tumor growth dynamics. (A) Simulated tumor 
growth in the case where oAd-MSCs neither promote nor suppress tumor cell proliferation (δp/s = 0).  
(B) Simulated tumor growth in the case where oAd-MSCs promote tumor cell proliferation, while (C) shows 
simulated tumor growth in the case where oAd-MSCs exert a suppressive effect on tumor cell proliferation. 
These simulations were conducted using the following parameters: (δp/s = 0.5), aT = 0.03545, KT = 5.14 × 1011 45, 
MOI = 5, with other parameters as in Table S1 in SI text.
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The multiplicity of infection is a key player in tumor reduction and its higher value leads to better treatment outcomes. 
We first took a more holistic view of the parameter space by performing a global sensitivity analysis using both 
Pearson Rank Correlation Coefficients (PRCC) and the extended Fourier Amplitude Sensitivity Testing (eFAST). 
Our sensitivity analysis (see Identification of key model parameters section in SI text) reveals that there is a var-
iability in parameters that influence tumor size at different time points corresponding to early and later stages of 
tumor growth. Under PRCC, the model system is found to be most sensitive to the multiplicity of infection (MOI) 
(see Fig. S1 in SI text) as well as to the half-saturation constant that supports half maximum killing of infected 
cells by the oncolytic virus. Most intriguingly, these parameters can easily be estimated from the experimental 
data. Furthermore, the eFAST results (see Fig. S2 in SI text), indicate that MOI is the most significant parameter 
affecting the early stages of tumor growth, while the virus clearance and the rate of CTL recruitment are most 
significant at latter time points. The qualitative results of our global sensitivity analysis show that the MOI is a key 
driver of tumor reduction. To further investigate this interesting result and to determine how loading MSCs with 
different MOI impacts the tumor lysis, we simulated different therapeutic profiles of tumor cell growth by varying 
MOI values as used in the oAd-MSC as described in our experiments. The resulting relative contributions of each 
MOI to tumor oncolysis are shown in Fig. S5 in SI text.
We note that lower loading of oncolytic Ads on MSCs does not lead to a decrease in the tumor size, instead 
the tumor growth is worsened by MSCs, indicating a treatment failure. On the other hand, at higher loading, 
we notice that not only the tumor is reduced to a small size, but is also rapidly debulked to a small size with the 
second dose of oAd-MSCs. More importantly, the tumor is kept at small size for longer therapeutic time window. 
Using this information, we can conclude that loading MSCs at various MOIs, within tolerable toxicities, may 
improve our current understanding of the therapy adjustments indispensable for successful oAd-MSC based 
treatment outcomes.
Our sensitivity analysis has significant impacts from both the mathematical and clinical research viewpoints. 
From the clinical perspective, the sensitivity analysis results suggest that, based on the variations of MOI, tumor 
cells can be more effectively controlled during the early growth phases (i.e., the oAd-MSC therapy is more likely 
to be successful during early tumor evolution), while at latter growth phases, the tumor is more likely to escape 
the therapy (i.e., failure of oAd-MSC therapy is more likely to occur during latter tumor growth phases). This 
could be due, partly, to high free virus clearance by the anti-virus immune cells (note that the virus clearance is 
statistically significant at days 70 and 200 - see Fig. S2 in SI text). This particular result is consistent with other 
models which highlight that increasing virus clearance leads to a larger tumor burden40. Taken together, these 
results elucidate how cell death, which depends on the multiplicity of infection according to this model, can affect 
clinical outcome. Thus, our sensitivity analysis highlights how parameter space screening to assess the cell death 
by oncolytic viruses can be useful in designing new oncolytic vectors for MSC-based treatments.
Anti-tumoral effect of oAd-MSC based therapy depends on their tumor promotive or suppressive 
action. Considering the fact that it is still currently a contentious debate whether MSCs exert a pro- or 
anti-tumor action8, numerical simulations such as the those conducted herein may aid to objectively predict the 
consequences of using MSCs for delivering oncolytic Ads in vivo. It is known that MSC-based therapies can produce 
varying outcomes in relation to secretion of cytokines and chemokines, and immunomodulatory potential24–26, 
making it difficult to predict how an individual patient may respond to MSC-cell based oncolytic virotherapy25.
Figure 4. The effect of increasing oAd-MSC dose on tumor cell lysis. A high dosage of 1 × 108 oAd-MSCs 
is injected into the system on days 9 and 13. The simulated tumor growth in the case where oAd-MSCs have 
no effect on tumor cell proliferation (δp/s = 0) is shown in (A). (B) Simulated tumor growth in the case where 
oAd-MSCs promote tumor cell proliferation. (C) Simulated tumor growth in the case where oAd-MSCs exert a 
suppressive effect on tumor cell proliferation. In (B,C), it is assumed that the oAd-MSCs have 50% (i.e., δp/s = 0.5) 
chance of either promoting or suppressing tumor proliferation, respectively. These simulations were conducted 
using the following parameters: aT = 0.03545, KT = 5.14 × 1011 45, and other parameters as in Table S1 in SI text.
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Our sensitivity analysis (see Fig. S1 in SI text) indicates that the model is sensitive to immune related param-
eters at latter times of tumor growth. At the latter growth stages, tumors often express different tumor antigens 
which are recognized by immune cells, and if on the other hand, the tumor can downregulate, modify or abrogate 
expression of these antigens, then it may find a way to avoid immune recognition. Our sensitivity analysis results 
further illustrate that the immune response may not be capable of controlling early tumor growth. This result is 
also confirmed by the simulations in Fig. S3 in SI text which show how a tumor evolves over time in the presence 
of the immune response. We therefore, herein examine the impact of oAd-MSCs on tumor growth when there is 
no immune response. To further investigate the anti-tumoral effect of using oAd-MSCs, we use our mathematical 
framework to simulate three different treatment protocols when: (a) oAd-MSCs do not have any effect on tumor 
growth; (b) oAd-MSCs promote tumor growth; and (c) oAd-MSCs suppress tumor growth.
(a) oAd-MSCs that do not have any effect on tumor growth offer moderate treatment outcomes. The simulation 
results, presented in Fig. 3(A), show that the oAd-MSC treatment exhibits potent killing effects, with cell killing of 
99.3% for tumor cells on day 35 suggesting that using oAd-MSCs that have no effect on tumor cell growth can still 
yield a favourable treatment outcome. We note, compared to cases (B) and (C), that oAd-MSCs that do not have 
any effect on tumor growth offer better treatment outcomes than oAd-MSCs that suppress tumor growth (case C).
(b) oAd-MSCs that promote tumor cell proliferation elicits highly effective anti-tumor responses. The results in 
Fig. 3(B) indicate that administering oAd-MSCs that promote tumor proliferation (i.e., prior to their lysis by 
oncolytic virions) effectively exhibited the greatest killing effects, with cell killing of 99.8% for tumor cells on day 
35. From both the modeling and clinical perspectives, this result shows that using oAd-MSCs which promote 
tumor proliferation exhibits higher tumor killing effects is very intriguing, and initially counter-intuitive. Despite 
the fact that MSCs promote the growth of tumors, infected MSCs (i.e., infected with the replicating virus, such as 
oncolytic Ad), typically die within 5 days from virus infection41. Promising as this observation is, future exper-
imental research is warranted to justify this observation. Results in Fig. 3(B), however, confirm the findings in 
the experiment that using oAd-MSCs results in effective tumor killing compared to anti-tumor effects of naked 
oncolytic Ads (see also Table S2 in SI text). Our numerical results are comparable to the findings in18 which 
Figure 5. Comparison of direct oncolytic Ads dose versus oAd-MSC dose. Comparison of direct oncolytic Ads 
dose with the dose of oAd-MSCs that promote tumor growth ((A) by 10%(δp/s = 0.1), (B) by 50%(δp/s = 0.5), 
and (C) by 90%(δp/s = 0.9)), and with oAd-MSCs that suppress tumor growth ((D) by 10%(δp/s = 0.1), (E) by 
50%(δp/s = 0.5), and (F) by 90%(δp/s = 0.9)). Note the following notation for treatment scenarios: No therapy 
(00), direct injection of naked oncolytic Ads only (01), injection of oAd-MSCs only (10). The low promotive/
suppressive probability (δp/s = 0.1) in (A,D) indicates negligible advantage of oAd-MSC therapy over the therapy 
naked oncolytic Ads. Also note that at higher probability (δp/s = 0.9), in (C,F), the oAd-MSC therapy reduces 
tumor burden faster than the naked oncolytic Ads. This indicates that if the oAd-MSCs have a high chance 
of promoting/suppressing tumor cell proliferation, then the oAd-MSC therapy provides better therapeutic 
outcomes, as compared with direct intravenous dose of naked oncolytic Ads.
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demonstrated that there was a decrease in tumor burden in mice treated with oncolytic Ad delivered by MSC 
carriers compared with the direct injection of the oncolytic Ad.
(c) oAd-MSCs that suppress tumor growth exhibit a lower tumor killing effect. Finally, we simulated the scenario 
where the oAd-MSCs exert a suppressive effect on tumor cell growth. Results are depicted in Fig. 3(C). We note 
that increasing the absolute value of tumor growth promotion/suppression constant in the model only increases 
the promotive/suppressive effect of oAd-MSC on tumor proliferation, but the model qualitatively demonstrated 
similar results under the three scenarios considered in this study (see Fig. S4 in SI text). From Fig. 3(C), we see 
that if the oAd-MSCs exert some suppressive effect on tumor cell growth, the treatment is significantly less effec-
tive than anticipated. Taken together, we conclude that using oAd-MSCs that promote tumor proliferation may 
provide a significant advantage in tumor cell reduction, though the therapeutic benefit of such oAd-MSCs may 
be limited if the oncolytic viruses do not successfully infect all tumor cells. Based on these results, if the goal of 
the therapy is to target long-term tumor control, using oAd-MSCs that have promotive effects on tumor growth 
offer better treatment outcomes. These results demonstrate that systemic delivery of oncolytic Ad by MSCs may 
provide a powerful alternative therapy to naked oncolytic Ad. As demonstrated by the simulations, we infer 
that, because the infected MSCs effectively delivered oncolytic Ads to the tumor site in experiments and in18, 
oAd-MSC based therapy surmounts the limited clinical applicability of system administration of oncolytic Ads 
and provides effective treatment to inaccessible tumors.
In silico simulations of oAd-MSC based therapeutic dynamics. Given the above observations, we 
further used our mathematical model to perform in silico simulations of oAd-MSC dynamics under two sce-
narios: High initial oAd-MSC inoculum and comparison of oAd-MSC with direct oAd therapies. The simula-
tion results we present here are purely hypothetical and require further investigations of this tumor treatment. 
Eventhough the simulation results are interpreted in the context of hypothetical clinical patient outcomes, the 
simulation settings align with the in vivo experiment in32, to mimic oAd-MSC based treatment regimes.
Increasing oAd-MSCs inoculum leads to a faster reduction of tumor burden. To investigate the dose-dependency 
of the initial oAd-MSC inoculum, we simulated the same three treatment scenarios discussed above with an 
increased value of 1 × 108 oAd-MSCs, under the same MOI of 10. While the initial oAd-MSC inoculum can 
be manipulated in clinical settings, we are predominantly interested in the dynamic interactions that can be 
observed in the human clinical setting, though it is conceivable that mouse experiments may emulate clinical 
settings. In any case, the initial oAd-MSC inoculum injected into patients would be higher than those considered 
in animal models24. Note that in our simulations here, we used the same number of oncolytic Ads (5 × 108 viral 
particles (VP)) as described in our experiments above, and increased number of MSCs (1 × 108 cells), generating 
MOI of 5, which is still within the clinical ranges reported in24. The results of this adjustment are shown in Fig. 4.
From Fig. 4(A), we see that the second dosage at day 13 of oAd-MSCs is able to drastically reduce the tumor 
size by 99.84% compared to what is in Fig. 3(A). It is interesting to note that although the oAd-MSCs injected do 
not impact a tumor in anyway, the progeny of oncolytic Ads released from oAd-MSCs is able to effectively reduce 
tumor to small sizes. Again, comparing Figs. 3(B) and 4(B), where oAd-MSCs promote tumor proliferation, we 
observe that the high dosage of oAd-MSCs is able to greatly reduce the tumor by approximately 99.87%. Finally, 
we also observe an enhanced tumor killing of approximately 100% in Fig. 4(C) compared to 99.9% in Fig. 3(C). 
For clinical applicability we adapted a high infusion of 1 × 108 oAd-MSCs (which is less than 3.0 × 108 cells (clin-
ical dose)41), and we noted that in Fig. 4, the second oAd-MSC dosage is capable of rapidly reducing tumors to 
small sizes compared to Fig. 3. This implies that tumors could be held in a small controllable state by the presence 
of oAd-MSCs, within the tumor microenvironment, which would ultimately produce a second progeny of Ads 
that can propagate and infect more tumor cells.
oAd-MSC therapy provides better therapeutic outcomes compared to direct oncolytic Ad therapy. Despite a grow-
ing need for the best therapeutic options, clinical goals are now turning towards optimization of long-term 
control of cancer, rather than a complete cure. Mathematical models are useful tools for enhancing our under-
standing of the optimal therapeutic options. In this regard, we chose to test the merit of oAd-MSC regimens by 
comparing them with direct intravenous injection of naked oncolytic Ads. In particular, we were interested in 
finding which therapy regimen leads to rapid tumor reduction. We assume that a treatment regimen that reduces 
a total tumor cell population rapidly, within the therapeutic window of 35 days as in the experiments herein, will 
offer a greater tumor control, minimize time to tumor relapse, and provide a better prognosis. In order to com-
pare the significance of each therapy, dependent on the influx terms (described in model Eqs. (3) and (4) which 
have switch boolean constants (ξM and ξV) defined in Eq. (9) in SI text), we held one term constant and vary the 
other according to the following therapy schedules: (1) no therapy; (2) direct injection of naked oncolytic Ads 
only; and (3) injection of oAd-MSCs. Note also that these treatment schedules are simulated in consideration of 
whether oAd-MSCs promote or suppress tumor cell proliferation and for different probabilities of tumor growth 
promotion/suppression by oAd-MSCs. The results are shown in Fig. 5.
In Fig. 5 (see also Table S2 in SI text), we note that when oAd-MSCs have a smaller likelihood of promoting 
or suppressing tumor cell growth, the oAd-MSC based regimen yields a relatively similar treatment outcome to 
direct dose of naked oncolytic Ads. Most importantly, when oAd-MSCs have a higher likelihood of suppressing 
tumor cell proliferation, our results (Fig. 5(F)) indicate that the oAd-MSC therapy outperforms the direct dose of 
naked oncolytic Ad therapy. In general, this result indicates that the oAd-MSC treatment is not only more effec-
tive at controlling tumor burden, but also reduces tumor size rapidly, suggesting that the oAd-MSC treatment has 
important therapeutic outcomes over the therapy with naked oncolytic Ads.
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In summary, the simulations conducted in this study shed light on different plausible treatment outcomes 
which may arise when using MSCs as cellular vehicles of oncolytic viruses. Importantly, though the above simu-
lations were done under hypothetical clinical settings, the simulation results are qualitatively comparable to the 
clinical results in42. For example, in42 a complete clinical response was observed in four children when MSCs were 
used as cellular carriers of oncolytic virus, and one of the four children was reported to have complete remission 
3 years after MSC-based oncolytic virotherapy. Taken together, our computational framework described herein 
may serve as a basic platform which can help to objectively assess the contribution of oAd-MSC based dynamics 
to clinical outcomes, as it is often difficult to predict how individual patients may respond to the MSC-based 
carrier therapies25.
Discussion and conclusion
In this paper, we devised a new mathematical model calibrated with a set of experimental data, including data 
from our own in vitro and in vivo experiments32, for the delivery of oncolytic Ads by MSCs. Even though math-
ematical models that describe the use of cells as carriers of therapeutic agents to tumor sites have been proposed 
in the literature (see for example30,31), no model has described the dynamics of tumor growth under MSC-based 
oncolytic virotherapy. Our quantitative framework is the first of its kind in that it not only describes the local 
interactions of tumor cells with oncolytic viruses and immune cells, but also incorporates the impact of MSC 
promotive/suppressive actions on tumor growth dynamics.
We quantified how model parameters influence tumor growth dynamics with global sensitivity analysis of the 
parameter space. The analysis revealed that the lysis rate of infected cells, which depends on the multiplicity of 
infection (MOI), is the most influential parameter. In particular, low variation in MOI suggests that the oncolytic 
Ads have a great potential of destroying tumor cells at all time points. This is qualitatively affirmed by the model 
simulations, especially in Fig. 4. In our fitting, we kept the multiplicity of infection (MOI = 5) constant because 
the MOI of 5 led to the optimal condition for viral production in32. However, comparison of lysis rates for tum-
ors treated with direct oAd with those treated with oAd-MSC suggests that the initial viral dose is an important 
variable and a key determinant of successful therapy. While higher initial viral dose may favor treatment with 
direct oncolytic virus, higher virus inoculum may critically induce premature MSC lysis (due to adenovirus rep-
lication), leading to decreased overall efficacy of oAd-MSC therapy32. We performed a global sensitivity analysis 
of the parameter space and model simulations with the current model and noticed that this is true. Experimental 
evidence from various tumor models with oAd support this conclusion11,32,43.
Based on this understanding, it seems that oAd-MSCs can significantly enhance oncolytic virotherapy. This 
may, at least in part, offer reasonable justification for why the use of MSCs as cellular vehicles of OVs appears to 
be the most attractive therapy in anti-tumor strategies. Altogether, our PRCC and eFAST results reveal that the 
lysis rate of infected cells is related to the enhanced oAd-MSC treatment efficacy, consistent with the experimental 
findings in16,17. We should emphasize that variation in lysis rate of infected cells could be more accurately quan-
tified given the availability of relevant patient-specific data, and the efficacy of oAd-MSCs as cellular vehicles is 
more likely to influence clinical outcomes. Therefore, quantifying MOI variations could provide a significant 
impact on the design of future oAd-MSC based therapies that target tumor cell proliferation.
We further used the model to investigate how systemic administration of oAd-MSC influences the treatment 
outcomes compared to direct administration of naked oncolytic Ads. In particular, we were predominantly inter-
ested in finding out how the dynamic interactions between oAd-MSCs and tumor cells impact the therapeutic 
outcome, under the notion that the Ad-MSCs may promote/suppress tumor proliferation. Given the low infusion 
of oAd-MSCs (Fig. 3(B)), we note that, though the tumor is effectively reduced, there is still a large number of 
uninfected tumor cells at the end of the experimental therapeutic window of 35 days. This offers a slight improve-
ment compared to the case where oAd-MSC have no influence on tumor growth (Fig. 3(A)). If, on the other 
hand, the oncolytic Ads cannot successfully infect a large portion of tumor cells, then this result suggests that 
oAd-MSCs could allow tumors to escape therapeutic control. This is in line with anti-tumoral studies indicating 
that MSCs promote tumor progression and metastasis in animal models8,44.
We alternatively simulated the scenario where oAd-MSCs suppress tumor growth (Fig. 3(C)), under low 
infusion of oAd-MSCs. We observed that the tumor is not greatly reduced as anticipated, compared to the pre-
vious scenario indicated in Fig. 3(B). This scenario is, however, still comparatively better than the case where 
oAd-MSCs exert no effect on tumor growth (Fig. 3(A)). This result suggests, at least from the clinical safety 
control perspective, that using oAd-MSCs that suppress tumor growth could still offer improved anti-tumor 
treatment outcomes. It is important to note that our model captures dynamical behaviour across a range of treat-
ment scenarios (three scenarios considered here). While each scenario is described by a specific choice of param-
eters, there is an intriguing underlying behaviour common to all scenarios. In particular, our model simulations 
explicitly display exponential tumor growth, indicating unbounded early tumor growth dynamics, and popula-
tion regression following the administration of oAd-MSC therapy, suggesting the feasibility and efficacy of using 
oAd-MSCs. In general, our results indicate that oAd-MSCs are capable of interacting with tumor cells in various 
ways which consequently lead to a reduced tumor cell population, consistent with both experimental and clinical 
studies18,24,42.
We also compared the therapeutic outcomes of injecting high oAd-MSC inoculum (emulating clinical set-
tings, similar to settings in24) to low dosage of oAd-MSC (emulating sub-clinical or experimental animal set-
tings) on tumor reduction. The results of high infusion of 1 × 108 oAd-MSCs are shown in Fig. 4, while results of 
injecting a small dose of 1 × 106 oAd-MSCs are indicated in Fig. 3. Investigation of tumor reduction revealed that 
high injection of oAd-MSCs causes, not only a faster reduction in tumor burden, but a massive reduction of the 
tumor under all three treatment scenarios. These results show a dose-dependent increase in tumor killing efficacy 
of oAd-MSC therapy, indicating that oncolytic Ads (delivered by MSCs) are capable of replicating efficiently 
and inducing tumor cell death. Based on this understanding, we conclude that treatment with high infusion of 
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oAd-MSCs provides a more useful tool compared with treatment with low injection of oAd-MSCs, consistent 
with the findings in24. It is crucial to note that even though we simulated therapeutic scenarios with high injection 
of oAd-MSCs, the cell viability of MSC post-infection decreases rapidly as shown in17, in particular, infected 
MSCs typically die within 5 days from virus infection as confirmed in41.
Having confirmed that the initial inoculum of oAd-MSCs plays a critical role in tumor control, we were inter-
ested in modeling how the MOI-dependency of oAd-MSC impacts treatment outcome. We showed that low 
MOIs may lead to treatment failure, while higher values of MOIs yield better results than previously thought, with 
tumor significantly reduced and maintained in small sizes (see Fig. 4). As demonstrated above, this finding high-
lights the need to find the right balance between the number of oAd-MSCs injected and the amount of oncolytic 
virions loaded on the MSCs for long term tumor control with OVs. The appropriate MOI adjustments can help 
determine the tumor size outcome with, possibly, a tumor-free state at the end of therapy. When comparing the 
therapeutic benefits of using oAd-MSC therapy to direct intravenous dose of naked oncolytic Ads, our simulation 
results (Fig. 5) point out that the oAd-MSC therapy offers qualitatively similar, but slightly better, prognosis with 
respect to rapid reduction of tumor cells, than the naked oncolytic Ad therapy. Thus, our results highlight an 
essential subtlety that can further be tested in future clinical trials focused on this comparison.
Our computational analysis provides new important insights into the properties of MSCs when used as cel-
lular vehicles for delivering oncolytic Ads to the tumor microenvironment. Understanding the dynamics of how 
tumors respond to oAd-MSC therapies can inform oncolytic virotherapy schedules and can provide basic guide-
lines for optimizing treatment response. Even though the results of this study are novel and promising, several 
limitations exist in the current modeling framework. With respect to the lysis term proposed here, model pre-
dictions may change as a function of multiplicity of infection (MOI) and the Hill coefficient (n), as confirmed 
by global sensitivity analysis results in Figs. S2 and S3. Even with these limitations, the lysis term proposed in 
this modeling approach allowed for the prediction of tumor response to oncolytic Ads delivered by MSCs, as 
observed in the oAd-MSC experiments we carried out. While no violation of model assumptions is observed, it is 
inherently difficult to test whether the antiviral immune response and anti-tumor immune response in the model 
are independently induced by OVs, as the experimental data in our study were derived from human xenograft 
tumor-bearing immunodeficient mice. Thus, it should be noted that the model predictions cannot be applied 
directly to the human clinical setting, and there is a need for robust model calibration and validation as appropri-
ate data become available.
Most of the parameters pertaining to the interaction of tumor cells, immune cells, and OVs used in the current 
model were obtained from previous models, which fitted models to experimental data from immunodeficient 
mice, due to lack equivalent data for human patients. We, therefore, emphasize that parameter re-evaluation is 
certainly warranted in future to perform rigorous model validation. While also conceivable that model predic-
tions may vary, the fundamental concepts relating to tumor growth promotion/suppression induced by MSCs are 
robust to parameter choice, and qualitatively similar results are expected to be observed. Importantly, optimiza-
tion of the oAd-MSC dosing regimens and incorporation of pharmacokinetic/pharmacodynamic terms describ-
ing the release of cytokines/chemokines by MSCs to promote/suppress tumor growth would be an attractive 
further extension of the current model.The presence of tumor growth promotive/suppressive cytokines/chemok-
ines within the tumor microenvironment could strongly influence the outcome of the local interactions of tumor 
cells with oAd-MSCs, immune cells, and OVs.
In conclusion, this study illustrates different tumor responses which are difficult to explain from the experi-
mental results alone. Specifically, this model provides a new theoretical approach for predicting tumor changes 
in response to oncolytic Ads in vivo delivered by MSCs. Despite the inherent simplifying assumptions in the 
proposed model, our computational approach may serve as a basic platform for further refinement of mathe-
matical models that describe tumor responses to cell-based virotherapies. Our model may, at least in part, offer 
justification to why oAd-MSCs should be used with great caution under clinical settings. Most importantly, our 
results highlight that oAd-MSCs provide a feasible synergism of oncolytic virotherapy when used as cellular deliv-
ery vehicles. Currently, clinical trials using MSCs as cellular vehicles for delivering OVs are under way and our 
mathematical framework adds new valuable information which may help to determine how MSCs may actually 
translate into meaningful clinical outcomes. Taken together, the findings in the present paper suggest oAd-MSC 
therapy as a promising therapeutic candidate for delivering oncolytic Ads for future clinical trials against aggres-
sive and inaccessible tumors.
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